RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a patient who experienced muscle spasms and mylagia.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Leerink remains bullish on Sarepta, views EMBARK study results favorably
- Sarepta announces topline results from EMBARK study
- Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan
- Sarepta reports preliminary Q4 net product revenue $638.2M
- Sarepta price target lowered to $165 from $182 at RBC Capital